CANbridge Looks Beyond Asia With AVEO's Oncology Drug
This article was originally published in PharmAsia News
Executive Summary
In its first venture outside of Asia and a rare move by a Chinese biopharma firm, CANbridge Life Sciences is acquiring global rights to AVEO's clinical-stage ErbB3 (HER3) inhibitory antibody candidate, in a step CANbridge’s CEO explains fits well with the company's global strategy and therapeutic focus.